- Q4 2023 Intellia Therapeutics Inc Earnings Call TranscriptFeb 22, 2024$27.81 (+4.98%)Earnings
- Intellia Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Q3 2023 Intellia Therapeutics Inc Earnings Call TranscriptNov 09, 2023$25.16 (-11.24%)Earnings
- Q2 2023 Intellia Therapeutics Inc Earnings Call TranscriptAug 03, 2023$39.2 (-1.45%)Earnings
- Intellia Therapeutics Inc To Discuss Interim Clinical Data from Ongoing First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema TranscriptJun 12, 2023
- Intellia Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) TranscriptMay 30, 2023
- Intellia Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q1 2023 Intellia Therapeutics Inc Earnings Call TranscriptMay 04, 2023$43.59 (+11.90%)Earnings
- Intellia Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Intellia Therapeutics Inc Earnings Call TranscriptFeb 23, 2023$38.44 (-1.57%)Earnings
- Intellia Therapeutics Inc Investor Event TranscriptNov 14, 2022
- Q3 2022 Intellia Therapeutics Inc Earnings Call TranscriptNov 03, 2022$52.78 (-3.69%)Earnings
- Intellia Therapeutics Inc at Chardan Genetic Medicines Conference TranscriptOct 03, 2022
- Intellia Therapeutics Inc 2022 Bradykinin Symposium TranscriptSep 16, 2022
- Q2 2022 Intellia Therapeutics Inc Earnings Call TranscriptAug 04, 2022$63.6 (-10.32%)Earnings
- Intellia Therapeutics Inc to Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study TranscriptJun 24, 2022
- Q1 2022 Intellia Therapeutics Inc Earnings Call TranscriptMay 05, 2022$51.35Earnings
- Intellia Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2022
- Intellia Therapeutics Inc Call To Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study TranscriptFeb 28, 2022
- Q4 2021 Intellia Therapeutics Inc Earnings Call TranscriptFeb 24, 2022$83.69 (-3.13%)Earnings
- Intellia Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Intellia Therapeutics Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) TranscriptNov 15, 2021
- Q3 2021 Intellia Therapeutics Inc Earnings Call TranscriptNov 04, 2021$137.66 (+2.43%)Earnings
- Intellia Therapeutics Inc Strategic Collaboration to Develop Novel Genomic Medicines TranscriptOct 13, 2021
- Q2 2021 Intellia Therapeutics Inc Earnings Call TranscriptAug 05, 2021$166.29 (+24.32%)Earnings
- Intellia Therapeutics Inc Call to Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study Corporate Call TranscriptJun 28, 2021
- Intellia Therapeutics Inc Launch of New Universal CAR-T Company with Cellex and Blackstone Life Sciences Corporate Call TranscriptJun 22, 2021
- Q1 2021 Intellia Therapeutics Inc Earnings Call TranscriptMay 06, 2021$66.59 (-9.38%)Earnings
- Intellia Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- Q4 2020 Intellia Therapeutics Inc Earnings Call TranscriptFeb 25, 2021$60.93 (-0.78%)Earnings
- Intellia Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 11, 2020
- Q3 2020 Intellia Therapeutics Inc Earnings Call TranscriptNov 05, 2020$24.4Earnings
- Q2 2020 Intellia Therapeutics Inc Earnings Call TranscriptAug 06, 2020$18.7Earnings
- Intellia Therapeutics Inc Annual Shareholders Meeting TranscriptJun 18, 2020
- Q1 2020 Intellia Therapeutics Inc Earnings Call TranscriptMay 07, 2020$12.45Earnings
- Intellia Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 10, 2020
- Q4 2019 Intellia Therapeutics Inc Earnings Call TranscriptFeb 27, 2020$12.54Earnings
- Q3 2019 Intellia Therapeutics Inc Earnings Call TranscriptOct 31, 2019$10.88Earnings
- Q2 2019 Intellia Therapeutics Inc Earnings Call TranscriptAug 01, 2019$16.78Earnings
- Intellia Therapeutics Inc Annual Shareholders Meeting TranscriptMay 21, 2019
- Q1 2019 Intellia Therapeutics Inc Earnings Call TranscriptMay 02, 2019$14.31 (-15.82%)Earnings
- Intellia Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 12, 2019
Intellia Therapeutics Inc Call To Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study Transcript
Good afternoon, and welcome to Intellia Therapeutics investor event to discuss the interim clinical results from the Phase I study of NTLA-2001. This conference is being recorded at the company's request and will be available on the company's website following the end of the call.
I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Thank you, operator, and good afternoon, everyone. Welcome to Intellia's presentation of additional interim data from the Phase I clinical trial of NTLA-2001 for the treatment of ATTR amyloidosis.
Earlier this afternoon, we issued a press release detailing the results from our ongoing study. This release and the accompanying slide presentation can be found on the Investors and Media section of Intellia's website at intelliatx.com. As a reminder, this call is being broadcast live, and a replay of the event will be archived on Intellia's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)